Published in J Virol on October 22, 2014
Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. World J Gastroenterol (2015) 0.79
IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System. PLoS One (2015) 0.78
Hepatitis C Virus Infection Induces Autophagy as a Prosurvival Mechanism to Alleviate Hepatic ER-Stress Response. Viruses (2016) 0.77
Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture. PLoS One (2015) 0.76
Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Sci Rep (2017) 0.75
A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One (2015) 0.75
ENT1 and treatment of viral diseases. Oncotarget (2015) 0.75
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 12.46
Plasma membrane contributes to the formation of pre-autophagosomal structures. Nat Cell Biol (2010) 6.41
Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
LC3 and Autophagy. Methods Mol Biol (2008) 3.59
The autophagosome: origins unknown, biogenesis complex. Nat Rev Mol Cell Biol (2013) 3.04
A comprehensive glossary of autophagy-related molecules and processes. Autophagy (2010) 2.00
Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol (2013) 1.95
Mammalian nucleoside transporters. Curr Drug Metab (2004) 1.75
Clathrin and phosphatidylinositol-4,5-bisphosphate regulate autophagic lysosome reformation. Nat Cell Biol (2012) 1.60
Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatology (2013) 1.50
Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol (2001) 1.50
Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin (2013) 1.32
Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol (2005) 1.28
The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci (2006) 1.28
Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol (2014) 1.16
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene (2012) 1.11
Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J Virol (2009) 1.07
The life cycle of human equilibrative nucleoside transporter 1: from ER export to degradation. Exp Cell Res (2011) 1.04
Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol (2011) 1.02
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology (2010) 1.00
Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res (2010) 0.99
HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol (2013) 0.97
Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One (2010) 0.95
Impact of the autophagy machinery on hepatitis C virus infection. Viruses (2011) 0.95
Mechanism of HCV's resistance to IFN-α in cell culture involves expression of functional IFN-α receptor 1. Virol J (2011) 0.93
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int (2012) 0.90
Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One (2014) 0.89
Changes in autophagic response in patients with chronic hepatitis C virus infection. Am J Pathol (2011) 0.89
Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat (1996) 0.85
Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant (2013) 0.85
Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol (2013) 0.84
Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation. PLoS One (2013) 0.82
Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin. Antiviral Res (2010) 0.81
ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. Antimicrob Agents Chemother (2012) 0.79
Host-based ribavirin resistance influences hepatitis C virus replication and treatment response. J Virol (2011) 0.78